InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,641.60
(
0.83%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
86.66
(
-0.29%
)
Bitcoin
59,046.35
(
-1.86%
)
Post# of 252478
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119978
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 204452

Tuesday, 04/18/2017 10:59:06 AM

Tuesday, April 18, 2017 10:59:06 AM

Post# of 252478
NVS, AGN collaborate on phase-2b for NASH combo:

http://finance.yahoo.com/news/allergan-expands-leading-research-development-051500371.html

The combination to be tested is AGN’s Cenicriviroc and NVS’ FXR agonist, LNJ452.

AGN obtained Cenicriviroc in the 2016 buyout of TBRA at an astonishing 498% premium (#msg-125266132).

NVS’ LNJ452 belongs to the same drug class as ICPT’s Ocaliva, GILD’s GS-9674, and ENTA’s EDP-305 (#msg-128917063).

Financial terms of NVS-AGN collaboration are not disclosed.

Please see #msg-129038646 and #msg-130518050 for related discussion.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up